Ocular pseudomyasthenia or ocular myasthenia ‘plus’

A warning to clinicians

G. Moorthy, M. M. Behrens, D. B. Drachman, T. H. Kirkham, D. L. Knox, N. R. Miller, Thomas L. Slamovits, S. J. Zinreich

Research output: Contribution to journalArticle

68 Citations (Scopus)

Abstract

Myasthenia gravis (MG) commonly presents with weakness and fatigability of the lids and extraocular muscles, which respond to treatment with anticholinesterase medication. However, certain intracranial mass lesions may mimic these features of MG; alternatively, MG may mask the signs of a coexistent intracranial mass. We describe 8 patients originally diagnosed as having MG by knowledgeable clinicians, in whom an intracranial lesion instead of, or in addition to, MG was later identified. The lesions included parasellar tumors and aneurysms. In patients presenting with clinical features of ocular MG, it is therefore essential to establish a definite diagnosis of MG, to exclude other possible causes of “pseudomyasthenia,” and to exclude other diseases that might be masked by coexisting myasthenic weakness. We recommend that patients with clinical features of MG limited to the ocular or cranial musculature be thoroughly evaluated for intracranial mass lesions, using CT or MRI if warranted.

Original languageEnglish (US)
Pages (from-to)1150-1154
Number of pages5
JournalNeurology
Volume39
Issue number9
StatePublished - 1989
Externally publishedYes

Fingerprint

Myasthenia Gravis
Oculomotor Muscles
Clinicians
Lesion
Warning
Cholinesterase Inhibitors
Muscle Weakness
Masks
Aneurysm

ASJC Scopus subject areas

  • Arts and Humanities (miscellaneous)
  • Clinical Neurology
  • Neuroscience(all)

Cite this

Moorthy, G., Behrens, M. M., Drachman, D. B., Kirkham, T. H., Knox, D. L., Miller, N. R., ... Zinreich, S. J. (1989). Ocular pseudomyasthenia or ocular myasthenia ‘plus’: A warning to clinicians. Neurology, 39(9), 1150-1154.

Ocular pseudomyasthenia or ocular myasthenia ‘plus’ : A warning to clinicians. / Moorthy, G.; Behrens, M. M.; Drachman, D. B.; Kirkham, T. H.; Knox, D. L.; Miller, N. R.; Slamovits, Thomas L.; Zinreich, S. J.

In: Neurology, Vol. 39, No. 9, 1989, p. 1150-1154.

Research output: Contribution to journalArticle

Moorthy, G, Behrens, MM, Drachman, DB, Kirkham, TH, Knox, DL, Miller, NR, Slamovits, TL & Zinreich, SJ 1989, 'Ocular pseudomyasthenia or ocular myasthenia ‘plus’: A warning to clinicians', Neurology, vol. 39, no. 9, pp. 1150-1154.
Moorthy G, Behrens MM, Drachman DB, Kirkham TH, Knox DL, Miller NR et al. Ocular pseudomyasthenia or ocular myasthenia ‘plus’: A warning to clinicians. Neurology. 1989;39(9):1150-1154.
Moorthy, G. ; Behrens, M. M. ; Drachman, D. B. ; Kirkham, T. H. ; Knox, D. L. ; Miller, N. R. ; Slamovits, Thomas L. ; Zinreich, S. J. / Ocular pseudomyasthenia or ocular myasthenia ‘plus’ : A warning to clinicians. In: Neurology. 1989 ; Vol. 39, No. 9. pp. 1150-1154.
@article{367570b6433e477bb9def515a9fad545,
title = "Ocular pseudomyasthenia or ocular myasthenia ‘plus’: A warning to clinicians",
abstract = "Myasthenia gravis (MG) commonly presents with weakness and fatigability of the lids and extraocular muscles, which respond to treatment with anticholinesterase medication. However, certain intracranial mass lesions may mimic these features of MG; alternatively, MG may mask the signs of a coexistent intracranial mass. We describe 8 patients originally diagnosed as having MG by knowledgeable clinicians, in whom an intracranial lesion instead of, or in addition to, MG was later identified. The lesions included parasellar tumors and aneurysms. In patients presenting with clinical features of ocular MG, it is therefore essential to establish a definite diagnosis of MG, to exclude other possible causes of “pseudomyasthenia,” and to exclude other diseases that might be masked by coexisting myasthenic weakness. We recommend that patients with clinical features of MG limited to the ocular or cranial musculature be thoroughly evaluated for intracranial mass lesions, using CT or MRI if warranted.",
author = "G. Moorthy and Behrens, {M. M.} and Drachman, {D. B.} and Kirkham, {T. H.} and Knox, {D. L.} and Miller, {N. R.} and Slamovits, {Thomas L.} and Zinreich, {S. J.}",
year = "1989",
language = "English (US)",
volume = "39",
pages = "1150--1154",
journal = "Neurology",
issn = "0028-3878",
publisher = "Lippincott Williams and Wilkins",
number = "9",

}

TY - JOUR

T1 - Ocular pseudomyasthenia or ocular myasthenia ‘plus’

T2 - A warning to clinicians

AU - Moorthy, G.

AU - Behrens, M. M.

AU - Drachman, D. B.

AU - Kirkham, T. H.

AU - Knox, D. L.

AU - Miller, N. R.

AU - Slamovits, Thomas L.

AU - Zinreich, S. J.

PY - 1989

Y1 - 1989

N2 - Myasthenia gravis (MG) commonly presents with weakness and fatigability of the lids and extraocular muscles, which respond to treatment with anticholinesterase medication. However, certain intracranial mass lesions may mimic these features of MG; alternatively, MG may mask the signs of a coexistent intracranial mass. We describe 8 patients originally diagnosed as having MG by knowledgeable clinicians, in whom an intracranial lesion instead of, or in addition to, MG was later identified. The lesions included parasellar tumors and aneurysms. In patients presenting with clinical features of ocular MG, it is therefore essential to establish a definite diagnosis of MG, to exclude other possible causes of “pseudomyasthenia,” and to exclude other diseases that might be masked by coexisting myasthenic weakness. We recommend that patients with clinical features of MG limited to the ocular or cranial musculature be thoroughly evaluated for intracranial mass lesions, using CT or MRI if warranted.

AB - Myasthenia gravis (MG) commonly presents with weakness and fatigability of the lids and extraocular muscles, which respond to treatment with anticholinesterase medication. However, certain intracranial mass lesions may mimic these features of MG; alternatively, MG may mask the signs of a coexistent intracranial mass. We describe 8 patients originally diagnosed as having MG by knowledgeable clinicians, in whom an intracranial lesion instead of, or in addition to, MG was later identified. The lesions included parasellar tumors and aneurysms. In patients presenting with clinical features of ocular MG, it is therefore essential to establish a definite diagnosis of MG, to exclude other possible causes of “pseudomyasthenia,” and to exclude other diseases that might be masked by coexisting myasthenic weakness. We recommend that patients with clinical features of MG limited to the ocular or cranial musculature be thoroughly evaluated for intracranial mass lesions, using CT or MRI if warranted.

UR - http://www.scopus.com/inward/record.url?scp=0024460564&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0024460564&partnerID=8YFLogxK

M3 - Article

VL - 39

SP - 1150

EP - 1154

JO - Neurology

JF - Neurology

SN - 0028-3878

IS - 9

ER -